Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response.
CD4+ T cells
CD8+ T cells
T cell receptor
breast cancer
tumor-infiltrating lymphocytes
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
20
07
2023
medline:
22
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) have predictive and prognostic value in breast cancer (BC) and exert a protective function against tumor growth, indicating that it is susceptible to treatment using adoptive cell transfer of TILs or T cell receptor (TCR)-based therapies. TCR can be used to identify naturally tumor-reactive T cells, but little is known about the differences in the TCR repertoires of CD4+ and CD8+ TILs. TCR high-throughput sequencing was performed using TILs derived from the initial cultures of 11 BC biopsies and expanded and sorted CD4+ and CD8+ TILs as well as using PBMCs from healthy donors expanded and sorted using the same methodology. Physicochemical TCR differences between T cell subsets were observed, as CD4+ TILs presented larger N(D)Nnt TRB sequences and with a higher usage of positively charged residues, although only the latest was also observed in peripheral T cells from healthy individuals. Moreover, in CD4+ TILs, a more restricted TCR repertoire with a higher abundance of similar sequences containing certain amino acid motifs was observed. Some differences between CD4+ and CD8+ TCRs were intrinsic to T cell subsets as can also be observed in peripheral T cells from healthy individuals, while other were only found in TILs samples and therefore may be tumor-driven. Notably, the higher similarity among CD4+ TCRs suggests a higher TCR promiscuity in this subset.
Identifiants
pubmed: 37600765
doi: 10.3389/fimmu.2023.1227766
pmc: PMC10436466
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227766Informations de copyright
Copyright © 2023 Aran, Lázaro, Marco, Molina, Abancó, Peg, Gión, Garrigós, Pérez-García, Cortés and Martí.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Med Insights Oncol. 2016 Apr 05;10(Suppl 1):31-9
pubmed: 27081325
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Med. 2015 Aug;21(8):914-921
pubmed: 26193344
Front Immunol. 2019 Feb 26;10:299
pubmed: 30863407
Front Immunol. 2020 Jan 09;10:2985
pubmed: 31993050
Nat Genet. 2016 Sep;48(9):995-1002
pubmed: 27479906
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301
pubmed: 32303540
Bioinformatics. 2017 Sep 15;33(18):2924-2929
pubmed: 28481982
Mol Ther. 2011 Mar;19(3):620-6
pubmed: 21157437
Diabetes. 2008 Aug;57(8):2099-106
pubmed: 18492786
J Leukoc Biol. 2016 Mar;99(3):505-13
pubmed: 26394815
Cell. 2020 Nov 25;183(5):1264-1281.e20
pubmed: 33091337
Nat Immunol. 2022 Mar;23(3):446-457
pubmed: 35177831
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
Clin Immunol. 2010 Jun;135(3):466-75
pubmed: 20181533
Nat Med. 2019 Aug;25(8):1243-1250
pubmed: 31332390
J Immunol. 2017 Oct 1;199(7):2203-2213
pubmed: 28923982
Front Immunol. 2021 Jul 20;12:715234
pubmed: 34354714
N Engl J Med. 2022 Jul 21;387(3):217-226
pubmed: 35857659
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Immunol Rev. 2012 Nov;250(1):10-31
pubmed: 23046120
PLoS Comput Biol. 2015 Nov 25;11(11):e1004503
pubmed: 26606115
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Nat Biotechnol. 2020 Oct;38(10):1194-1202
pubmed: 32341563
Nature. 2023 Mar;615(7953):687-696
pubmed: 36356599
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Semin Immunol. 2007 Aug;19(4):216-24
pubmed: 17398114
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
PLoS Comput Biol. 2021 Jan 19;17(1):e1008486
pubmed: 33465095
Cell. 2018 Sep 20;175(1):85-100.e23
pubmed: 30173916
Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10409-E10417
pubmed: 29138313
FEBS Open Bio. 2019 Aug;9(8):1450-1459
pubmed: 31237075
Front Mol Biosci. 2022 Aug 19;9:903065
pubmed: 36060249
Int J Cancer. 2019 Feb 15;144(4):818-827
pubmed: 30151844
Bioinformatics. 2017 Sep 15;33(18):2938-2940
pubmed: 28645171
Science. 2006 Oct 6;314(5796):126-9
pubmed: 16946036
Nat Rev Immunol. 2012 Sep;12(9):669-77
pubmed: 22918468
J Immunol. 2005 Mar 1;174(5):2563-72
pubmed: 15728462
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406543
Cancer Immunol Res. 2017 Feb;5(2):148-156
pubmed: 28039161
EBioMedicine. 2019 Sep;47:414-426
pubmed: 31477563
Nat Rev Immunol. 2018 Jul;18(7):467-478
pubmed: 29636542
Int Immunol. 2004 Mar;16(3):423-31
pubmed: 14978016
Cancer Biol Med. 2019 May;16(2):350-360
pubmed: 31516755